Felix S.
- Country
- Germany
- Department
- Klinik und Poliklinik für Strahlentherapie
Research Overview
- Phase III Randomized Study of Durvalumab with SBRT and Osimertinib in Unresected Stage I/II Lymph-Node Negative NSCLC with EGFR Mutation
- Evaluation of Durvalumab in Combination with Cisplatin, Carboplatin, and Etoposide with Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Phase III Trial of Short-Course Radiotherapy vs. Chemoradiotherapy with Capecitabine, Fluorouracil, and Oxaliplatin in Intermediate/High-Risk Rectal Cancer
Data & Insights
Has run more than one trial at 19 of 151 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular emphasis on early-stage disease management.
- Radiation therapy integration
- Immunotherapy applications
- Targeted therapy approaches
The research encompasses innovative combinations of radiotherapy with immunotherapeutic agents for enhanced treatment outcomes.
Gastrointestinal Oncology
The investigator focuses on advanced treatments for rectal cancer and esophageal squamous cell carcinoma, with expertise in organ preservation strategies.
- Multimodal therapy approaches
- Organ preservation techniques
- Chemoradiotherapy protocols
Their work includes developing treatment protocols that balance therapeutic efficacy with quality of life considerations.
Therapeutic Innovation
The investigator explores novel therapeutic combinations including immunotherapy agents and targeted molecular treatments across various cancer types.
- Combined modality treatments
- Stereotactic radiotherapy
- Maintenance therapy strategies
Research focuses on integrating innovative treatment approaches with established therapeutic modalities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.